Long Focus Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Long Focus Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-215,000	Closed	-$195K	–	115
2024 Q3	$195K	Hold	215,000	–	–	0.02%	96
2024 Q2	$214K	Hold	215,000	–	–	0.02%	97
2024 Q1	$318K	Hold	215,000	–	–	0.04%	92
2023 Q4	$234K	Hold	215,000	–	–	0.03%	105
2023 Q3	$254K	Hold	215,000	–	–	0.04%	105
2023 Q2	$303K	Hold	215,000	–	–	0.05%	99
2023 Q1	$323K	Hold	215,000	–	–	0.05%	99
2022 Q4	$252K	Hold	215,000	–	–	0.04%	98
2022 Q3	$243K	Hold	215,000	–	–	0.05%	95
2022 Q2	$340K	Hold	215,000	–	–	0.07%	94
2022 Q1	$331K	Hold	215,000	–	–	0.07%	93
2021 Q4	$527K	Buy	+215,000	New	+$503K	0.14%	84

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $35.3B AUM 33.54% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return